Prognostic Value of Survivin in Locally Advanced Prostate Cancer: Study Based on RTOG 8610
| Autor: | Min Zhang, Elizabeth H. Hammond, R. Jeffrey Lee, Arnab Chakravarti, R. Scott Bermudez, Alan Pollack, Alex Ho, Li Yan Khor, Michael V. Pilepich, Yoshiyuki Suzuki, William U. Shipley, Howard M. Sandler |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Oncology Cytoplasm Cancer Research medicine.medical_specialty Multivariate analysis Antineoplastic Agents Hormonal Survivin medicine.medical_treatment Article Inhibitor of Apoptosis Proteins Prostate cancer Prostate Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Aged Randomized Controlled Trials as Topic Cell Nucleus Analysis of Variance Univariate analysis Radiation business.industry Hazard ratio Prostatic Neoplasms Androgen Antagonists Prognosis medicine.disease Immunohistochemistry Confidence interval Neoplasm Proteins Radiation therapy medicine.anatomical_structure Clinical Trials Phase III as Topic business Microtubule-Associated Proteins |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 73:1033-1042 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2008.06.1489 |
| Popis: | Purpose To examine the prognostic value of nuclear and cytoplasmic survivin expression in men with locally advanced prostate cancer who were enrolled in Radiation Therapy Oncology Group (RTOG) protocol 8610. Methods and Materials RTOG 8610 was a Phase III randomized study comparing the effect of radiotherapy plus short-term androgen deprivation with radiotherapy alone. Of the 456 eligible patients, 68 patients had suitably stained tumor material for nuclear survivin analysis and 65 patients for cytoplasmic survivin. Results Compared with patients with nuclear survivin intensity scores of ≤191.2, those with intensity scores >191.2 had significantly improved prostate cancer survival (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.20–1.00, p = 0.0452). On multivariate analysis, nuclear survivin intensity scores >191.2 were significantly associated with improved overall survival (HR, 0.46; 95% CI, 0.25–0.86; p = 0.0156) and prostate cancer survival (HR, 0.36; 95% CI, 0.16–0.84; p = 0.0173). On univariate analysis, compared with patients with cytoplasmic survivin integrated optical density ≤82.7, those with an integrated optical density >82.7 showed a significantly increased risk of local progression (HR, 2.49; 95% CI, 1.03–6.01; p = 0.0421). Conclusion Nuclear overexpression of survivin was associated with improved overall and prostate cancer survival on multivariate analysis, and cytoplasmic overexpression of survivin was associated with increased rate of local progression on univariate analysis in patients with locally advanced prostate cancer treated on RTOG 8610. Our results might reflect the different functions of survivin and its splice variants, which are known to exist in distinct subcellular compartments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|